Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)
Inhibrx Biosciences, Inc
Inhibrx Biosciences, Inc
DEKA Biosciences
Eli Lilly and Company
GlaxoSmithKline
City of Hope Medical Center
Synta Pharmaceuticals Corp.